Naphthyridine-Azaquinolone reverses Huntington’s DNA repeats in mouse model
Researchers show Naphthyridine-Azaquinolone (NA) could be a possible future therapy able to slow the progression and improve the symptoms of Huntington’s disease.
List view / Grid view
Researchers show Naphthyridine-Azaquinolone (NA) could be a possible future therapy able to slow the progression and improve the symptoms of Huntington’s disease.
Research into the role of non-coding DNA in cancer development and progression has identified 30 regions that may contribute to tumour growth, which could be therapeutic targets.
Researchers have discovered that inhibiting the ID1 protein slows the growth of glioblastoma tumours and reduces resistance to chemotherapy.